Market Research Logo

Global Cancer Vaccine Partnering 2010-2018: Deal trends, players and financials

Global Cancer Vaccine Partnering 2010-2018: Deal trends, players and financials

The Global Cancer Vaccine Partnering 2012-2018 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 250 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Key benefits

Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Cancer Vaccine deal trends since 2012
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
Identify most active Cancer Vaccine dealmakers since 2012
Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Terms and Agreements includes:

Trends in Cancer Vaccine dealmaking in the biopharma industry since 2012
Analysis of Cancer Vaccine deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Cancer Vaccine deals
Access to Cancer Vaccine contract documents
Leading Cancer Vaccine deals by value since 2012
Most active Cancer Vaccine dealmakers since 2012

In Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 250 Cancer Vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

  • Executive Summary
  • Introduction
  • Trends in Cancer Vaccine dealmaking
    • Introduction
    • Cancer Vaccine partnering over the years
    • Most active Cancer Vaccine dealmakers
    • Cancer Vaccine partnering by deal type
    • Cancer Vaccine partnering by therapy area
    • Deal terms for Cancer Vaccine partnering
      • Cancer Vaccine partnering headline values
        • Table Cancer Vaccine deals with a headline value
      • Cancer Vaccine deal upfront payments
        • Table Cancer Vaccine deals with an upfront value
      • Cancer Vaccine deal milestone payments
        • Table Cancer Vaccine deals with a milestone value
      • Cancer Vaccine royalty rates
        • Table Cancer Vaccine deals with a royalty rate value
  • Leading Cancer Vaccine deals
    • Introduction
    • Top Cancer Vaccine deals by value
      • Table Top Cancer Vaccine deals by value since 2010
  • Most active Cancer Vaccine dealmakers
    • Introduction
    • Most active Cancer Vaccine dealmakers
    • Most active Cancer Vaccine partnering company profiles
      • National Cancer Institute
      • ImmunoCellular Therapeutics
      • Advaxis
      • Inovio Pharmaceuticals
      • MedImmune
      • Pfizer
      • Scancell
      • GlaxoSmithKline
      • Immunovaccine
      • University of Pennsylvania
      • Immune Design
      • Mayo Clinic
      • National Institutes of Health
      • TapImmune
      • Aduro BioTech
      • Bavarian Nordic
      • Dana-Farber Cancer Institute
      • Merck and Co
      • OncoSec Medical
      • Transgene
      • Genentech
      • Immatics Biotechnologies
      • Neon Therapeutics
      • Novartis
      • Progenitor Cell Therapy
  • Cancer Vaccine contracts dealmaking directory
    • Introduction
    • Cancer Vaccine contracts dealmaking directory
  • Cancer Vaccine dealmaking by technology type
    • Vaccines
    • Attenuated vaccine
    • Conjugate vaccine
    • DNA vaccine
    • Recombinant vector vaccine
  • Partnering resource center
    • Online partnering
    • Partnering events
    • Further reading on dealmaking
  • Appendices
    • Cancer Vaccine deals by company A-Z
      • 2A
      • A*STAR Bioprocessing Technology Institute
      • Accelovance
      • Adamis Pharmaceuticals
      • AdnaGen
      • Aduro BioTech
      • Advanced BioScience Laboratories
      • Advaxis
      • AEterna Zentaris
      • Affitech
      • Agenus Bio
      • Agilent Technologies
      • Aldevron
      • Alliance for Biosecurity
      • Alnylam Pharmaceuticals
      • Amaran Biotechnology
      • Amarna Therapeutics
      • American Dental Association
      • Analytical Bio-Chemistry Laboratories
      • AnGes MG
      • Annias Immunotherapeutics
      • Antigen Express
      • Antitope
      • Apceth
      • Ariad Pharmaceuticals
      • Aslan Pharma
      • Asterias Biotherapeutics
      • AstraZeneca
      • Astrimmune
      • Aura Biosciences
      • Averion
      • Batu Biologics
      • Bavarian Nordic
      • Bayer Innovation
      • Baylor College
      • Baylor College of Medicine
      • Baylor Institute for Immunology Research
      • Baylor Research Institute
      • Beijing Genomics Institute (BGI)
      • Bellicum Pharmaceuticals
      • Beth Israel Deaconess Medical Center
      • BIND Biosciences
      • BinnoPharm
      • BioAlliance Pharma
      • BioClones
      • BioNTech
      • Biooutsource
      • BioSante Pharmaceuticals
      • Biotech Synergy
      • BioTime
      • BioVaxys
      • BioVest
      • Bluebird Bio
      • Boehringer Ingelheim
      • Bonnie J. Addario Lung Cancer Foundation
      • Bpifrance
      • Bristol-Myers Squibb
      • Broadvector
      • Broad Institute
      • Brown University
      • Caladrius Biosciences
      • California Institute of Technology
      • Cancer Immunotherapy Trials Network
      • Cancer Prevention and Research Institute of Texas
      • Cancer Research Institute
      • Cancer Research Technology
      • Cancer Research UK
      • Cancer Research Wales
      • Cardiff University
      • Catalan Institute of Nanotechnology (ICN)
      • Catherex
      • Celldex Therapeutics
      • Cellular Biomedicine
      • Center for Biomarker Research in Medicine
      • Centogene
      • ChemRar High-Tech Center
      • Chugai Pharmaceutical
      • CiMaas
      • City of Hope Comprehensive Cancer Center
      • Cleveland BioLabs
      • Clinipace Worldwide
      • Cobra Biologics
      • Colby Pharmaceuticals
      • Cristal Therapeutics
      • CSIRO
      • CureLab Oncology
      • CureVac
      • Cyplasin Biomedical
      • CYTLIMIC
      • Daiichi Sankyo
      • Dainippon Sumitomo Pharma
      • Dalton Pharma Services
      • Dana-Farber Cancer Institute
      • DanDrit Biotech
      • DCPrime
      • Delta-Vir
      • Dendreon
      • Department of Defense
      • Diosynth
      • DxS
      • Eli Lilly
      • EMD Serono
      • Emory University
      • Epimmune
      • EpiThany
      • Etubics
      • European Union
      • Federal Ministry of Education and Research (BMBF)
      • Formatech
      • Forska and Vax
      • Fraunhofer Institute for Cell Therapy and Immunology
      • Fred Hutchinson Cancer Research Center
      • G-Con
      • Galena Biopharma
      • Genentech
      • Generex Biotechnology
      • Genetic Immunity
      • Genexine
      • GenoLac
      • Genomic Expression
      • GenVec
      • Georgetown University
      • Georgia Health Sciences University
      • GeoVax
      • German Cancer Research Center
      • GISCAD Foundation
      • GlaxoSmithKline
      • Government of Rwanda
      • Gritstone Oncology
      • Hanmi Pharmaceutical
      • Harvard University
      • Heat Biologics
      • HemaCare
      • HemispheRx Biopharma
      • Henry M. Jackson Foundation
      • Hoffmann La Roche
      • Human Vaccines Project
      • IBio
      • Icahn School of Medicine at Mount Sinai
      • Ichor Medical Systems
      • IGNITE Immunotherapy
      • Immatics Biotechnologies
      • ImmuneRegen BioSciences
      • Immune Design
      • Immunicum
      • ImmunID Technologies
      • ImmunoCellular Therapeutics
      • Immunomic
      • ImmunoPhotonics
      • Immunovaccine
      • Immunovo
      • Inovio Pharmaceuticals
      • Intensity Therapeutics
      • InteRNA Technologies
      • IRX Therapeutics
      • Jaiva Technologies
      • Janssen Pharmaceuticals
      • Jantibody Therapeutics
      • Japan Vaccine
      • Jennerex
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • John Hopkins University School of Medicines
      • John P. Hussman Foundation
      • JSC Binnopharm
      • Juvaris BioTherapeutics
      • KAEL-GemVax
      • KellBenx
      • Leukaemia & Lymphoma Research
      • London Genetics
      • Ludwig Institute for Cancer Research
      • Lung Cancer Research Foundation
      • MabVax Therapeutics
      • Madison Vaccines
      • MannKind Biopharmaceuticals
      • Massachusetts General Hospital
      • Mayo Clinic
      • MDxHealth
      • MD Anderson Cancer Center
      • Medac
      • MediGene
      • MedImmune
      • Memorial Sloan Kettering Cancer Center
      • Merck and Co
      • Merck KGaA
      • Methodist Hospital Research Institute
      • Ministry of Industry and Trade of the Russian Federation
      • Moderna Therapeutics
      • Morphogenesis
      • MorphoSys
      • Nanobiotix
      • NantBioScience
      • NantKwest
      • National Cancer Institute
      • National Cancer Research Center
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Dental and Craniofacial Research (NIDCR)
      • National Research Council Canada
      • NEC
      • Neon Therapeutics
      • Netherlands Cancer Institute
      • NeuClone
      • Neumedicines
      • Newlink Genetics
      • NewVac
      • Northwest Biotherapeutics
      • Norwegian Cancer Society
      • Norwegian Research Council
      • Nottingham City Council
      • Novartis
      • Novartis Animal Health
      • NYU Langone Medical Center
      • Ohio State University
      • Omnimmune
      • Omnis Pharmaceuticals
      • OncoPep
      • OncoQR
      • OncoSec Medical
      • Oncotherapy Science
      • Oncothyreon
      • Oncovir
      • Ono Pharmaceutical
      • OSE Pharma (Orphan Synergy Europe Pharma)
      • Oxford BioMedica
      • Oxford Immunotec
      • Panacea Pharmaceuticals
      • Panacela Labs
      • Pepscan Therapeutics
      • Pfenex
      • Pfizer
      • PharmaCell
      • Pharmanet/i3
      • PharmaNet Development Group
      • PharmaPraxis
      • PlantForm
      • PPD
      • PRIMA BioMed
      • Profectus Biosciences
      • Progenitor Cell Therapy
      • Prostate Cancer Foundation (PCF)
      • Provecs Medical
      • PsiOxus Therapeutics
      • PX Biosolutions
      • Qiagen
      • Radboud University Nijmegen Medical Centre
      • Radient Pharmaceuticals
      • RareCyte
      • Regeneron Pharmaceuticals
      • Regen BioPharma
      • Research Institute of the Hospital Universitari Vall d'Hebron
      • Riyadh Pharma
      • Roche
      • RXi Pharmaceuticals
      • Sanofi
      • San Martino Hospital
      • Scancell
      • Selecta Biosciences
      • Selexis
      • Sellas Clinicals Holding
      • Serum Institute of India
      • Shenzhen BioScien Pharmaceuticals
      • SillaJen
      • Skolkovo Foundation
      • SOTIO
      • Spotlight Innovation
      • SRI International
      • Stanford University
      • Stellar Biotechnologies
      • Stellar Pharmaceuticals
      • Stemline Therapeutics
      • Susan G. Komen for the Cure
      • TapImmune
      • Tasly Pharmaceuticals
      • Telormedix
      • Teva Pharmaceutical Industries
      • Theravectys
      • The International AIDS Vaccine Initiative
      • The Regents of the University of California
      • Thomas Jefferson University
      • ToleRx
      • Torrey Pines Institute for Molecular Studies
      • Transgene
      • Transgene Tasly Biopharmaceutical
      • Treos Bio
      • TYG oncology
      • UbiVac
      • UK Government
      • University of Alabama at Birmingham
      • University of California, San Diego
      • University of Chicago
      • University of Copenhagen
      • University of Greifswald
      • University of Massachusetts Medical School
      • University of Miami
      • University of North Carolina
      • University of Pennsylvania
      • University of Pennsylvania School of Veterinary Medicine
      • University of Pittsburgh
      • University of Queensland
      • University of Rostock
      • University of Rouen
      • University of South Florida
      • University of Texas at El Paso
      • University of Turin
      • University of Western Ontario
      • Vaccibody
      • Vaccine and Gene Therapy Institute of Florida (VGTI-FL)
      • Vaccinogen
      • Vaxeal
      • Vaxil BioTherapeutics
      • Vaximm
      • Vedantra Pharmaceuticals
      • VGX International
      • Vinnova
      • ViroMed
      • Vivalis
      • VLP Therapeutics
      • VLST Corporation
      • VU University Amsterdam
      • Vyriad
      • Washington University in St Louis
      • Weill Cornell Medical College
      • Western Oncolytics
      • Wistar Institute
      • Wyss Institute
      • Xencor
      • Y-mAbs Therapeutics
      • Yale University
      • Yamaguchi University
    • Cancer Vaccine deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
    • Cancer Vaccine deals by deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Co-promotion
      • CRADA
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Material transfer
      • Option
      • Promotion
      • Research
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • Cancer Vaccine deals by therapy area
      • Oncology
      • Adenocarcinoma
      • Bladder cancer
      • Brain cancer
      • Breast cancer
      • Cervical cancer
      • Colorectal cancer
      • Gastric cancer
      • Head and neck cancer
      • Kidney cancer
      • Leukemia
      • Acute lymphoblastic leukemia
      • Acute myelogenous leukemia
      • Liver cancer
      • Lung cancer
      • Non small cell lung cancer
      • Small cell lung cancer
      • Lymphoma
      • Non Hodgkin's lymphoma
      • Melanoma
      • Mesothelioma
      • Multiple myeloma
      • Neuroblastoma
      • Ovarian cancer
      • Pancreatic cancer
      • Prostate cancer
      • Renal cell carcinoma
      • Solid tumors
      • Oral mucositis
      • Radiotherapy
      • Testicular cancer
      • Thyroid cancer
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report